American Life Science Pharmaceuticals, Inc. (ALSP, Inc.) Appoints Col. (Retired) Dallas Hack, MD as Consultant

SAN DIEGO, Feb. 10, 2016 /PRNewswire/ -- ALSP, Inc. announced that it has appointed Col.(Retired) Dallas C. Hack, MD as Consultant for Medical Affairs in preparation for its move into clinical trials with its lead drug.

Michael Pierschbacher, PhD, CEO, stated, "We are pleased to welcome Dallas Hack onto the ALSP team. We look forward to working with an individual of such practical knowledge and far-reaching experience in Traumatic Brain Injury (TBI). We look forward to drawing deeply on his broad experience and success as a clinician and researcher in this area as we enter into our next stage of growth, clinical development."

Since 2008, Col. Dallas Hack, MD was the director of the Combat Casualty Care Research Program and Chair, Joint Program Committee 6 (Combat Casualty Care), U.S. Army Medical Research and Materiel Command, Fort Detrick, MD, coordinating leading edge-research focused on TBI. He also served as the Chair of Joint Technology Coordinating Group 6 of the Armed Services Biomedical Research Evaluation and Management (ASBREM) Committee. He has been awarded numerous medals, including the Bronze Star and Legion of Merit.

Dr. Hack graduated from Loma Linda University School of Medicine in 1976. After a rotating internship in Anesthesiology and a fellowship in Cardiology and Biomathematics, he worked in General Practice and Biomedical Engineering for 9 years, serving as Vice President of Engineering for a number of biomedical companies. He was recruited into active duty in September 1987, to modernize clinical research at the US Army Medical Research Institute of Infectious Diseases (USAMRIID) completing a residency in General Preventive Medicine in 1995. He also has a MPH from Johns Hopkins, a Master of Strategic Studies from the U.S. Army War College, and a CPE from the Certifying Commission in Medical Management.

Dr. Hack commented, "It is an honor to join such an experienced scientific and business team who are exceptionally dedicated to pushing back the boundaries of treatments for TBI, AD and other neurodegenerative diseases. This leading-edge work is vitally important."

About ALSP, Inc.
ALSP, Inc. is a privately held company in San Diego, California, developing small molecule drugs for treating neurodegenerative diseases, initially focused on TBI and Alzheimer's Disease (AD).
Further  information: www.alspinc.com

Forward-Looking Statements:
This release contains "forward-looking statements" as defined under U.S. federal securities laws.

SOURCE American Life Science Pharmaceuticals, Inc.

Related Links

http://www.alspinc.com